The firm is currently involved in hormone drug litigation. The hormone drugs at issue are suspected to promote breast cancer. The drugs involved in the litigation are Prempro, Premphase, Premarin, Provera, and many others. Women who took these drugs had an increased risk, by as much as two to one, of developing certain types of breast cancer. The drugs were prescribed for women over the age of 35 for long-term treatment of menopausal symptoms, depression, nervousness, anxiety, dementia, heart protection, and prevention of osteoporosis and bone loss.
The drugs were not approved by the FDA (Food and Drug Administration) for all of these conditions.
For instance, hormone drugs were improperly promoted as being “heart healthy” when studies actually show increased risks of serious heart conditions. The drugs were marketed for the prevention of post-menopausal osteoporosis. However, other drugs, without the side effects of hormone therapy, were available for treating osteoporosis. Lobular breast cancer and hormone receptor positive ductal cancer have been linked to the drugs. The women affected may require a lumpectomy and/or mastectomy. These women may also require chemotherapy, radiation, and anti-estrogen cancer drugs. Although hormone products are still being sold by drug companies, instead of the previous long-term therapy promotions, some drugs are now being recommended for limited periods of time and at their lowest effective doses.
Members of the firm are currently representing over 250 hormone drug plaintiffs. The cases have all been transferred to the MDL (Multi-District Litigation) in the Eastern District of Arkansas. Tom Dutton has been involved in national discovery efforts and is a member of the Plaintiffs’ Governing Committee.